SPOTLIGHT -
Switching to a patient case of brain metastases in HER2+ breast cancer, panelists highlight available therapeutic strategies in this setting.
FDA Gives Fast Track Designation to IDE161 for HR+, HER2– Breast Cancer
The safety and tolerability of IDE161 is being assessed as part of a phase 1 trial in solid malignancies including breast cancer.
Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment
Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.
Ribociclib/Aromatase Inhibitors Maintain HRQOL in HR+, HER2– Breast Cancer
A health-related quality of life analysis of the phase 3 NATALEE trial supports the risk/benefit profile of adding ribociclib to nonsteroidal aromatase inhibitors in patients with hormone receptor–positive, HER2-negative early breast cancer.
Oncology On-The-Go Podcast: Time to Treatment for Breast Cancer in Rural Populations
Minh-Tri Nguyen, MD, spoke with CancerNetwork® about differences between time to treatment, socioeconomic status, and clinical outcomes in rural and urban patients with breast cancer.
Neratinib Combo Yields Meaningful Benefit in HR+ HER2-Mutant Breast Cancer
Responses in patients with hormone receptor–positive, HER2-mutated breast cancer who crossed over to receive neratinib plus fulvestrant and trastuzumab support the necessity of neratinib in the triplet regimen.
FDA Clears IND Application for First-in-Class CDK12/13 Inhibitor
A planned phase 1 trial will examine CDK12/13 inhibitor CT7439 in patients with several types of solid tumors, including breast and ovarian cancer, as well as Ewing’s sarcoma.